Clywedog Therapeutics, Inc. CLYD

Company Overview

Barinthus Biotherapeutics plc is a clinical-stage biotechnology company focused on developing immunotherapeutic products and vaccine platforms for infectious diseases, autoimmune disorders, and oncology. The company operates within the biotechnology and biopharmaceutical industries and is publicly traded on Nasdaq under the ticker CLYD. Barinthus is best known for its differentiated T-cell immunotherapy approach, leveraging viral vector and synthetic platform technologies designed to generate durable immune responses against chronic diseases and cancer targets.

The company’s primary programs have historically centered on chronic hepatitis B virus (HBV) infection, human papillomavirus (HPV)-related cancers, and other immune-mediated diseases. Its core revenue profile has largely consisted of collaboration agreements, licensing arrangements, research partnerships, and capital raised through equity financing, as the company remains in the clinical development stage and does not currently market approved commercial therapeutics. Barinthus evolved from Vaccitech plc, which was founded as a spinout from the University of Oxford and became known for its contributions to viral vector vaccine technology. The company later rebranded to Barinthus Biotherapeutics to reflect a broader strategic focus beyond prophylactic vaccines into immunotherapeutics and immune modulation.